What Is Alyftrek? The 2024 Cystic Fibrosis Approval
Alyftrek is a once-daily combination of three CFTR modulators approved in December 2024 for eligible people aged six and older with cystic fibrosis.
Timeline
- December 20, 2024: FDA approved Alyftrek for eligible patients with cystic fibrosis.
- 52-week trials: Alyftrek was compared with elexacaftor, tezacaftor and ivacaftor after a four-week run-in.
The U.S. Food and Drug Administration approved Alyftrek on December 20, 2024 to treat cystic fibrosis in people aged six years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene. Genetic eligibility is therefore part of the approved use. [1][2]
Alyftrek combines three active ingredients: vanzacaftor, tezacaftor and deutivacaftor. They are CFTR modulators, medicines designed to improve the function of defective cystic fibrosis transmembrane conductance regulator protein in people whose mutations respond. The treatment addresses the protein defect but does not remove the underlying inherited mutation. [1]
The medicine is taken by mouth once daily. Tablet strength and the number of tablets depend on age, and the prescribing information governs administration with fat-containing food and management of missed doses. “Once daily” distinguishes the schedule from some earlier modulator combinations; it does not mean one tablet is correct for every patient. [1][2]
FDA based the original approval on two Phase 3 noninferiority trials involving 971 participants. Everyone first received elexacaftor, tezacaftor and ivacaftor for four weeks, then was randomly assigned to continue that comparator or switch to Alyftrek for 52 weeks. The main endpoint measured change in percent-predicted FEV1 through week 24. [1]
Alyftrek was noninferior, meaning it met the prespecified standard for not being unacceptably worse than the established comparator on lung function. The studies also examined pulmonary exacerbations, patient-reported respiratory outcomes and sweat chloride. Noninferiority is a defined statistical conclusion and does not mean two treatments are identical in every respect. [1]
The FDA summary lists respiratory symptoms, headache, fatigue, rash and increased liver enzymes among common adverse reactions. Serious liver injury has occurred with related modulator therapy, and liver-function blood testing is recommended before and during treatment. Drug interactions and existing liver disease can affect whether and how Alyftrek is used. [1]
The approval broadens treatment options for people with responsive CFTR mutations, but it is not suitable for every person with cystic fibrosis. Mutation testing, age, other medicines and liver status all matter. The FDA snapshot explains the original evidence, while the latest prescribing information should control individual medical decisions. [1][2]